4/A: Pasithea Therapeutics Director Corrects Stock Option Exercise Price in Amended SEC Filing
SEC Filing (Form 4/A)
Alfred J. Novak, a director of Pasithea Therapeutics Corp., filed an amended Form 4 to correct the exercise price of a stock option granted on March 1, 2024.
Summary
- Alfred J. Novak, a director of Pasithea Therapeutics Corp., filed an amended Form 4 with the SEC.
- The purpose of the amendment is to correct the exercise price of a stock option previously reported as $8.34 per share.
- The correct exercise price is $8.13 per share, based on the closing price of Pasithea Therapeutics' common stock on March 1, 2024.
- The stock option was granted on March 1, 2024, for 5,000 shares and will vest over three years.
- A reverse stock split of 1-for-20 was effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing correcting a minor error. It doesn't contain information that would significantly impact investor sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It doesn't necessarily reflect broader industry trends but is specific to Pasithea Therapeutics' equity compensation practices.
Stakeholder Impact
- The correction of the stock option exercise price ensures accurate reporting to shareholders.
Key Dates
| Date | Description |
|---|---|
| 2024-01-02 | Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 |
| 2024-03-01 | Date of original filing and transaction date for stock option grant with corrected exercise price of $8.13. |
| 2024-04-05 | Date of amended filing (Form 4/A). |
| 2034-02-28 | Expiration date of the stock option. |
Keywords
Form 4, Pasithea Therapeutics, Stock Option, Director, Amendment, KTTA, Reverse Stock Split
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.